Jeffrey Wuitschick
Director, R&D Abbott Molecular
Seminars
Wednesday 7th October 2026
From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution
2:10 pm
- Essential attributes of a high‑performing CDx
- Executing complex, multi‑stakeholder CDx programs
- How CDx experience accelerates market, regulatory, and clinical success
